A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

• ClinicalTrials.gov Identifier: NCT05275673
• Recruitment Status: Recruiting
• First Posted: March 11, 2022
• Last Update Posted: November 9, 2022
• Sponsor: Calithera Biosciences, Inc
• Information provided by (Responsible Party): Calithera Biosciences, Inc

Study Description

Brief Summary:

This is a multicenter, randomized, open-label Phase 2 study of sapanisertib in biomarker-defined populations of sqNSCLC. Patients with NFE2L2 (the name for gene encoding the protein called NRF2)-mutated or wild-type sqNSCLC should have disease that has progressed on or after at least two prior systemic therapies for metastatic disease including platinum-doublet chemotherapy and a programmed cell death 1 ligand 1 (PD-L1) inhibitor. The study will evaluate sapanisertib monotherapy in patients with relapsed/refractory sqNSCLC as two separate groups: Group A: NFE2L2-mutated sqNSCLC and Group B: NFE2L2-WT sqNSCLC.

Condition or disease	Intervention/treatment	Phase
Non-Small Cell Lung Cancer; Squamous Non-small-cell Lung Cancer; Squamous Non-Small Cell Neoplasm of Lung; NFE2L2 Gene Mutation	Drug: sapanisertib	Phase 2

Detailed Description:

NFE2L2 mutation status for all patients will be identified using local or central next generation sequencing (NGS) testing on archival or fresh tissue or circulating tumor deoxyribonucleic acid (ctDNA), the results of which must be reviewed and approved by the Sponsor prior to enrollment. Each group will be randomized 1:1 to one of two doses/schedules of sapanisertib. Approximately 30 NFE2L2-mutant and 20 NFE2L2-wild type patients will be enrolled. Patients will be treated with sapanisertib until disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), unacceptable toxicity, withdrawal of consent, or death.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 50 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment

Intervention Model Description

2 dosing schedules: 3 mg once per day (3 mg total) OR 2 mg twice per day (4 mg total)

Group A: 30 participants randomized 1:1 to one of two dosing schedules

Group B: approximately 20 participants randomized 1:1 to one of two dosing schedules

• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Randomized, Open-Label Phase 2 Study of the TORC 1/2 Inhibitor Sapanisertib in Relapsed/Refractory NFE2L2 (NRF2)-Mutated and Wild-Type (WT) Squamous Non-Small Cell Lung Cancer (sqNSCLC)
• Actual Study Start Date: April 15, 2022
• Estimated Primary Completion Date: September 30, 2023
• Estimated Study Completion Date: March 31, 2025

Arms and Interventions

Arm	Intervention/treatment
Experimental: Group A - NFE2L2 Mutation, Dosing Cohort 1; sapanisertib 3 mg once daily (QD)	Drug: sapanisertib; capsules for oral administration; Other Name: CB-228
Experimental: Group A - NFE2L2 Mutation, Dosing Cohort 2; sapanisertib 2 mg twice daily (BID)	Drug: sapanisertib; capsules for oral administration; Other Name: CB-228
Experimental: Group B - NFE2L2 Wild-Type, Dosing Cohort 1; sapanisertib 3 mg QD	Drug: sapanisertib; capsules for oral administration; Other Name: CB-228
Experimental: Group B - NFE2L2 Wild-Type, Dosing Cohort 2; sapanisertib 2 mg BID	Drug: sapanisertib; capsules for oral administration; Other Name: CB-228

Outcome Measures

Primary Outcome Measures :

1. Investigator-Assessed Overall Response Rate (ORR) per RECIST v1.1. [ Time Frame: 36 months ]
   ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) according to the RECIST v1.1 criteria as assessed by the investigator.
2. Number of Participants With Adverse Events (AEs), Serious AEs, Deaths, and Discontinuations Due to AEs [ Time Frame: after the first dose of study drug through 28 days after the last dose of sapanisertib (up to 36 months) ]
   An adverse event (AE) is any untoward, undesired, or unplanned medical occurrence in a patient administered a medicinal product whether or not considered drug related. A serious adverse event (SAE) is an AE that occurs after receiving study treatment (or after signing informed consent and before receiving study treatment if due to a protocol-mandated procedure) that either results in death, is life-threatening, requires inpatient hospitalization, results in persistent or significant disability, results in congenital anomaly or birth defect, or otherwise meets criteria as an important medical event.

Secondary Outcome Measures :

1. Duration of Response (DOR) [ Time Frame: 36 months ]
   DOR will be calculated as the time between the first documentation of partial response (PR) or a complete response (CR) to the first documentation of progressive disease or death, whichever occurs first.
2. Progression-Free Survival (PFS) [ Time Frame: 36 months ]
   PFS is defined as the time from randomization to the first occurrence of disease progression as determined by the investigator using RECIST v1.1 or death from any cause, whichever occurs first.
3. Overall Survival (OS) [ Time Frame: 36 months ]
   OS is defined as the time from randomization to death due to any cause.
4. Overall Survival (OS) at 6 Months [ Time Frame: 6 months ]
   OS is defined as the time from randomization to death due to any cause.
5. Overall Survival (OS) at 12 Months [ Time Frame: 12 months ]
   OS is defined as the time from randomization to death due to any cause.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Stage IV squamous NSCLC.
• Disease progression during or after prior systemic therapy for metastatic disease, which must include platinum-doublet chemotherapy and immune checkpoint inhibitor therapy (anti-PD-(L)1 +/-anti-CTLA-4), if approved and available, administered as separate lines of therapy or in combination.
• Has study-eligible mutation in NFE2L2 or wild-type NFE2L2 using NGS from a College of American Pathologists- (CAP)-accredited and/or a Clinical Laboratory Improvement Amendments- (CLIA)-certified laboratory
• Must have at least one radiographically measurable lesion per RECIST v1.1 defined as a lesion that is ≥ 10 mm in longest diameter or lymph node that is ≥ 15 mm in short axis imaged by computerized tomography (CT) scan or Magnetic Resonance Imaging (MRI).
• Target lesions situated in a previously irradiated area may be considered measurable if progression has been demonstrated subsequent to radiation therapy.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
• Adequate Organ Function Laboratory Findings: Absolute neutrophil count (ANC): ≥1,500/mm3, Hemoglobin: ≥9.0 g/dL * Transfusions and growth factors must not be used within 2 weeks prior to randomization to meet these requirements, Platelets: ≥ 100,000/mm3, Calculated creatinine clearance (CrCl): ≥ 40mL/min, Serum total bilirubin: ≤ 1.5× upper limit of normal (ULN) OR ≤ 3 mg/dL for patients with Gilbert's disease, AST (SGOT) and ALT (SGPT): ≤ 2.5× ULN OR ≤ 5× ULN for patients with liver metastases, Fasting triglycerides: < 300 mg/dL, Fasting serum glucose: <160 mg/dL

• A female patient of childbearing potential must:

  1. Have a negative serum or urine pregnancy test within 7 days prior to the first dose of study treatment
  2. Agree to use acceptable methods of contraception(See Section 8.1.2) during the study and for a minimum of 14 days following the last dose of sapanisertib
  3. Post-menopausal females (no menses for >1 year without an alternative medical cause) and surgically sterilized females are exempt from these requirements.
• Male patients must use an effective barrier method of contraception if sexually active with a female of childbearing potential and refrain from donating sperm during the study and for a minimum of 14 days following the last dose of sapanisertib.

Exclusion Criteria:

• Non-squamous cell histology and mixed histology tumors with any small-cell/neuroendocrine component.
• Prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment per investigator's discretion.

• Receipt before the first dose of study drug of any of the following:

  i. Any investigational agent within 4 weeks. ii. Chemotherapy with 3 weeks (6 weeks for nitrosoureas or mitomycin C) iii. Any radiotherapy within 2 weeks prior to randomization with the exception of palliative radiotherapy for isolated tumor lesions

• Major surgery or other anticancer therapy not previously specified within 4 weeks.
• Unable or unwilling to discontinue proton pump inhibitor (PPI) use ≥ 5 days prior to randomization.
• Interstitial lung disease or a history of pneumonitis that required oral or intravenous glucocorticoid treatment.
• Any condition including social, psychiatric or medical (including uncontrolled significant concurrent illness) that in the opinion of the Investigator could interfere with treatment or protocol-related procedures.
• Patients who are pregnant or lactating.
• Symptomatic ascites or pleural effusion. Exception: Patients who are clinically stable following treatment for these conditions (including therapeutic thoraco-or paracentesis) are eligible.
• Refractory nausea and vomiting, uncontrolled diarrhea, malabsorption, significant small bowel resection or gastric bypass surgery, use of feeding tubes or other situation that may preclude adequate absorption of oral study medication.
• Infection requiring more than 5 days of parenteral antibiotics, antivirals, or antifungals within two weeks prior to randomization.
• Patients receiving systemic corticosteroids greater than prednisone 10 mg or equivalent (excluding inhalers or low-dose hormone replacement therapy) within the 7 days before treatment initiation.
• Previous intolerance to mammalian target of rapamycin (mTOR), AKT, or dual PI3K/mTOR inhibitors.
• Patients with symptomatic, active/untreated central nervous system metastasis and/or leptomeningeal disease are not eligible.
• Significant active cardiovascular disease
• Participants who are known to be HIV-positive, unless assessed to be healthy with a low risk of AIDS-related outcomes.
• Known active Hepatitis B or C infection.
• Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of the study drug.

Contacts and Locations

Contacts

Contact: Clinical Administrator; 650-870-1000; clinicaltrials@calithera.com

Locations

United States, California

UC Davis Comprehensive Cancer Center; Recruiting

Davis, California, United States, 95817

Contact: Nicole Terry 916-734-4913 nicterry@ucdavis.edu

Providence Medical Group Santa Rosa - Cancer Center; Recruiting

Santa Rosa, California, United States, 95403

Contact: Teresa Lund 707-521-3803 teresa.lund@stjoe.org

Contact: Tracy Foster tracy.foster@stjoe.org

Principal Investigator: Ian C Anderson, MD

United States, Florida

Florida Cancer Specialists; Recruiting

Fort Myers, Florida, United States, 33901

Contact: Lowell Hart, MD Clinicaltrials@FLCancer.com

Principal Investigator: Lowell Hart, MD

Ocala Oncology Center; Recruiting

Ocala, Florida, United States, 34474

Contact: Sanjit Nirmalanandhan 352-732-4032 Sanjit.Nirmalanandhan@usoncology.com

Principal Investigator: Rama Balaraman, MD

Florida Cancer Specialists; Recruiting

Tallahassee, Florida, United States, 32308

Contact: Augusto Villegas, MD ClinicalTrials@FLCancer.com

Principal Investigator: Augusto Villegas, MD

United States, Kentucky

Norton Cancer Institute, Downtown; Recruiting

Louisville, Kentucky, United States, 40202

Contact: John Hamm, MD 502-629-2500 Lung-NCIResearch@nortonhealthcare.org

Principal Investigator: John Hamm, MD

United States, Michigan

Karmanos Cancer Institute; Recruiting

Detroit, Michigan, United States, 48201

Contact: Hirva Mamdani, MD 313-576-8711 mamdanih@karmanos.org

Principal Investigator: Hirva Mamdani, MD

United States, Missouri

Washington University - Patient Care Coordinator Center; Recruiting

Saint Louis, Missouri, United States, 63110

Contact: PCCC 314-747-7222 Patient_Care_Coordination_Center@bjc.org

Contact 800-600-3606

United States, New York

Memorial Sloan Kettering Cancer Center - Thoracic; Recruiting

New York, New York, United States, 10065

Contact: Paul Paik, MD 646-888-4202 paikp@mskcc.org

Principal Investigator: Paul Paik, MD

United States, Ohio

Zangmeister Cancer Center; Recruiting

Columbus, Ohio, United States, 43219

Contact: Nancy Zangmeister 614-383-6236 Nancy.Zangmeister@aoncology.com

Principal Investigator: Jorge Rios, MD

United States, Oregon

Providence Cancer Institute Franz Clinic; Not yet recruiting

Portland, Oregon, United States, 97213

Contact: Julie Cramer, MA 412-952-5634 Julie.Cramer@providence.org

Principal Investigator: Rachel Sanborn, MD

United States, Pennsylvania

UPMC Cancer Pavilion; Recruiting

Pittsburgh, Pennsylvania, United States, 15232

Contact: Jennifer Ruth 412-623-8963 ruthj2@upmc.edu

Principal Investigator: Taofeek Owonikoko, MD

United States, Tennessee

Tennessee Oncology; Recruiting

Nashville, Tennessee, United States, 37203

Contact: Kelly Goddard, RN DDUreferrals@sarahcannon.com

Principal Investigator: Melissa Johnson, MD

United States, Virginia

Virginia Cancer Specialist, PC; Recruiting

Fairfax, Virginia, United States, 22031

Contact: Carrie Friedman, RN 703-636-1473 Carrie.Friedman@usoncology.com

Principal Investigator: Alexander Spira, MD

Sponsors and Collaborators

Calithera Biosciences, Inc

Investigators

• Study Director: Bradley J Sumrow, MD; Calithera Biosciences, Inc

More Information

• Responsible Party: Calithera Biosciences, Inc
• ClinicalTrials.gov Identifier: NCT05275673
• Other Study ID Numbers: CX-228-301
• First Posted: March 11, 2022
• Last Update Posted: November 9, 2022
• Last Verified: October 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No
• Plan Description: We do not plan to share the individual participant data with other researchers

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Calithera Biosciences, Inc:

NSCLC; sqNSCLC; NFE2L2; Next Generation Sequencing; NGS; Mutation; Relapsed; Refractory; Squamous; NRF2; Lung Cancer

Additional relevant MeSH terms:

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms